Lapatinib Tablet
Product Images NDC 68180-801

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lapatinib (NDC 68180-801). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 4

A Kaplan-Meier survival curve showing cumulative progression-free survival over time (months) since randomization for three groups: Lapatinib (1000 mg) plus Trastuzumab with AI, Lapatinib (1500 mg) with AI, and Trastuzumab with AI. The y-axis represents cumulative progression-free survival, and the x-axis represents time in months.*

FDA Label Image

Lapatinib Chemical Structure (Lapatinib Fig1)

Chemical structure of lapatinib, showing its molecular arrangement including rings, nitrogen atoms, chlorine, fluorine, and sulfonyl groups.*

FDA Label Image

Lapatinib Study Graph (Lapatinib Fig2)

A Kaplan-Meier curve showing cumulative progression-free survival over time in weeks. The graph compares three groups: Lapatinib tablets (250 mg), Capecitabine (2,000 mg/m2), and a combined Lapatinib plus Capecitabine group, illustrating differences in progression-free survival rates among the treatments.*

FDA Label Image

Lapatinib Study Graph (Lapatinib Fig3)

A Kaplan-Meier survival curve graph showing canine progression-free survival over time (weeks) for three treatment groups: Lapatinib tablets (1,250 mg/kg) combined with Capecitabine (2,000 mg/m2), Capecitabine alone (2,500 mg/m2), and Capecitabine (2,000 mg/m2). The Y-axis represents canine progression-free survival proportion, and the X-axis represents time in weeks.*

FDA Label Image

Lapatinib Study Graph (Lapatinib Fig4)

A Kaplan-Meier survival curve chart comparing progression-free survival over time in weeks for Lapatinib tablets (1,500 mg) combined with Letrozole (2.5 mg) versus Letrozole (2.5 mg) alone. The y-axis represents cumulative progression-free survival.*

FDA Label Image

Lapatinib Tablets Label (Lapatinib Label)

Lapatinib Tablets 250 mg oral tablets packaging label shows a bottle containing 150 tablets. It is labeled with the National Drug Code (NDC) 68180-801-36 and manufactured by Natco Pharma Limited, India, and distributed by Lupin Pharmaceuticals, Inc. in the United States. The label includes storage instructions, safety warnings, and barcode information.*

FDA Label Image

Lapatinib Vizag Label

Label for Lapatinib Tablets 250 mg oral tablets, containing 150 tablets per package. The label lists Lapatinib as the active ingredient, specifies storage instructions, and includes manufacturer Natco Pharma Limited (India) and distributor Lupin Pharmaceuticals, Inc. (Baltimore, MD). The NDC is 68180-801-36.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.